Loading...
Market
Will Moderna's mRNA-1083 vaccine be available on the market by September 30, 2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Official product launch announcements from Moderna, retail availability
Story
Moderna's mRNA-1083 Combo COVID-19 and Flu Vaccine Shows Strong Phase 3 Results
Jun 10, 2024, 01:10 PM
Moderna announced that its investigational combination vaccine, mRNA-1083, which targets both COVID-19 and seasonal influenza, has shown positive results in a Phase 3 late-stage trial. The vaccine generated a stronger immune response in adults aged 50 and over compared to separate shots for each virus. The combination vaccine was found to be more effective than existing standalone vaccines, including Moderna's own Spikevax. The success of the trial brings Moderna closer to potentially filing for regulatory approval, with market availability anticipated as early as fall 2025. Moderna CEO Stephane Bancel highlighted the convenience and potential benefits of combination vaccines, especially in the context of labor shortages in healthcare.
View original story
Similar markets
Under $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Phase 3 trial initiation • 33%
Phase 3 trial completion • 33%
FDA submission • 34%
